SwePub - search: WFRF:(Imoukhuede Egeruan B)

Enumeration	Reference	Cover	Find
1.	Geels, Mark J, et al. (author) European Vaccine Initiative : lessons from developing malaria vaccines 2011 In: Expert Review of Vaccines. - : Informa UK Limited. - 1476-0584 .- 1744-8395. ; 10:12, s. 1697-1708 Journal article (peer-reviewed)abstract For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 2009) has contributed to the development of 24 malaria candidate vaccine antigens with 13 vaccine candidates being advanced into Phase I clinical trials, two of which have been transitioned for further clinical development in sub-Saharan Africa. Since its inception the EVI organization has operated as a funding agency, but with a clear service-oriented strategy. The scientific successes and difficulties encountered during these years and how these efforts have led to standardization and harmonization in vaccine development through large-scale European consortia are discussed. In the future, the EVI will remain instrumental in the pharmaceutical and clinical development of vaccines against ?diseases of poverty? with a continued focus on malaria. EVI will continue to focus on funding and managing preclinical evaluation up to Phase I/II clinical trials and strengthening the vaccine-development infrastructure in Europe, albeit with a global orientation.

Geels, Mark J, et al. (author)
European Vaccine Initiative : lessons from developing malaria vaccines
2011
In: Expert Review of Vaccines. - : Informa UK Limited. - 1476-0584 .- 1744-8395. ; 10:12, s. 1697-1708
Journal article (peer-reviewed)abstract
- For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 2009) has contributed to the development of 24 malaria candidate vaccine antigens with 13 vaccine candidates being advanced into Phase I clinical trials, two of which have been transitioned for further clinical development in sub-Saharan Africa. Since its inception the EVI organization has operated as a funding agency, but with a clear service-oriented strategy. The scientific successes and difficulties encountered during these years and how these efforts have led to standardization and harmonization in vaccine development through large-scale European consortia are discussed. In the future, the EVI will remain instrumental in the pharmaceutical and clinical development of vaccines against ?diseases of poverty? with a continued focus on malaria. EVI will continue to focus on funding and managing preclinical evaluation up to Phase I/II clinical trials and strengthening the vaccine-development infrastructure in Europe, albeit with a global orientation.

Träfflista för sökning "WFRF:(Imoukhuede Egeruan B) "